STRO · XBRL financial data

Sutro Biopharma financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (STRO's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025†Dec 31, 2025
Revenue from contracts with customers	42,722	61,880	67,772	153,731	62,043	102,484
Research and development	76,961	104,400	137,171	180,425	252,043	166,417
General and administrative	36,818	56,004	59,544	62,584	48,453	41,019
Total operating expenses	113,779	160,404	196,715	243,009	300,496	260,851
Operating income (loss)	(71,057)	(98,524)	(128,943)	(89,278)	(238,453)	(158,367)
Interest expense	2,300	2,600	2,400	1,300	—	—
Income tax expense (benefit)	100	0	2,500	18,192	2,363	(93)
Net income (loss)	(32,128)	(105,538)	(119,204)	(106,793)	(227,461)	(191,086)
Earnings per share, basic‡ USD per share	(9.90)	(22.90)	(23.50)	(17.80)	(29.60)	(22.49)
Earnings per share, diluted‡ USD per share	(9.90)	(22.90)	(23.50)	(17.80)	(29.60)	(22.49)
Weighted average shares, basic‡ thousands of shares	3,257	4,612	5,074	6,016	7,683	8,498
Weighted average shares, diluted‡ thousands of shares	3,257	4,612	5,074	6,016	7,683	8,498

‡ Per-share figures and share counts are adjusted for the 1-for-10 stock split (December 2025); filings made before it reported them unadjusted.
† Share count changed about 2x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (STRO's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025†Dec 31, 2025
Cash and cash equivalents	206,152	30,414	47,254	69,268	190,304	58,130
Marketable securities	120,341	130,343	255,090	264,413	126,591	83,298
Marketable securities, non-current	0	68,775	0	0	0	0
Accounts receivable	5,559	12,454	7,122	36,078	8,616	3,977
Prepaid and other current assets	4,486	8,123	11,667	9,846	17,799	5,521
Total current assets	378,182	218,515	353,153	421,542	343,310	150,926
Property and equipment, net	12,935	22,550	24,621	21,940	18,190	10,648
Right-of-use asset	—	29,041	26,443	22,815	17,677	10,903
Total assets	394,111	341,408	406,944	470,736	387,207	173,830
Accounts payable	5,544	11,327	4,797	9,440	10,475	7,565
Accrued liabilities	8,823	11,417	13,142	14,686	12,905	14,642
Current portion of long-term debt	—	9,375	12,500	4,061	—	—
Total current liabilities	29,597	41,736	66,547	93,746	131,893	75,133
Long-term debt	24,545	15,738	3,771	0	—	—
Lease liability, non-current	—	31,224	29,574	23,154	15,674	7,891
Total liabilities	62,063	88,844	189,896	321,087	342,606	306,282
Accumulated deficit	(227,873)	(333,411)	(452,615)	(559,408)	(786,869)	(977,955)
Total stockholders' equity	332,048	252,564	217,048	149,649	44,601	(132,452)
Total liabilities and equity	394,111	341,408	406,944	470,736	387,207	173,830
Common shares outstanding (cover page)‡ thousands of shares	4,589	4,638	6,016	6,244	8,378	16,567

‡ Per-share figures and share counts are adjusted for the 1-for-10 stock split (December 2025); filings made before it reported them unadjusted.
† Share count changed about 2x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (STRO's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025†Dec 31, 2025
Net income (loss)	(32,128)	(105,538)	(119,204)	(106,793)	(227,461)	(191,086)
Stock-based compensation	11,917	23,241	26,304	24,908	24,687	14,008
Depreciation and amortization	4,297	4,844	5,690	6,816	7,218	7,324
Net cash from operating activities	(67,802)	(81,679)	3,549	(111,616)	(191,540)	(177,231)
Net cash from investing activities	604	(97,315)	(35,022)	(3,924)	218,508	45,013
Proceeds from issuing common stock	251,415	—	56,270	11,971	25,000	0
Share repurchases	—	7	—	—	—	—
Net cash from financing activities	269,247	3,256	48,313	137,554	94,054	44
Net change in cash	202,049	(175,738)	16,840	22,014	121,022	(132,174)

† Share count changed about 2x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Sutro Biopharma	54,335	9,839	(38,290)*	16.6M	4.3 quarters	Q2 FY26 10-QJun 30, 2026
PDS Biotechnology	5,596	not reported	(2,793)*	56.0M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
Medicinova	25,416	458	(1,920)*	49.2M	13.2 quarters	Q2 FY26 10-QJun 30, 2026
iBio	56,395	0*	(6,228)*	64.3M	14.1 quarters	Q4 FY26 10-KJun 30, 2026
Lifevantage	14,920	42,377*	4,767*	12.5M	—	Q4 FY26 10-KJun 30, 2026
Veru	23,880	not reported	(5,467)*	17.1M	4.4 quarters	Q3 FY26 10-QJun 30, 2026
Whitehawk Therapeutics	85,234	0	(14,529)*	57.0M	13.1 quarters	Q2 FY26 10-QJun 30, 2026
Avalo Therapeutics	85,382	not reported	(19,988)*	53.6M	20.0 quarters	Q2 FY26 10-QJun 30, 2026
Mersana Therapeutics	56,391	11,009	(3,192)*	5.0M	17.7 quarters	Q3 FY25 10-QSep 30, 2025

Not investment advice. Not affiliated with the U.S. SEC.